» Articles » PMID: 22848092

REST is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma

Overview
Journal Mol Cancer Ther
Date 2012 Aug 1
PMID 22848092
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Medulloblastoma is a malignant pediatric brain tumor. Current treatment following patient stratification into standard and high-risk groups using clinical features has improved survival. However, a subset of patients with standard risk features have unanticipated aggressive disease, underscoring the need for a better understanding of tumor biology and the development of novel treatments. Poor differentiation, a hallmark of medulloblastomas is associated with elevated expression levels of the repressor of neuronal differentiation called repressor element 1-silencing transcription factor (REST). Here, we assessed whether elevated REST expression levels had prognostic significance and whether its pharmacologic manipulation would promote neurogenesis and block tumor cell growth. REST levels in patient tumors were measured by immunohistochemistry and stratified into negative, low/moderate- (+/++/+++), and high-REST (+++++) groups. Kaplan-Meier curves revealed that patients with high-REST tumors had worse overall and event-free survival compared with patients with REST-negative or REST-low tumors. Because histone deacetylases (HDAC) are required for REST-dependent repression of neurogenesis, we evaluated a panel of HDAC inhibitors (HDACI) for their effects on growth and differentiation of established and primary REST-positive cell lines. MS-275, trichostatin-A (TSA), valproic acid (VPA), and suberoylanilide hydroxamic acid (SAHA) upregulated expression of the REST-target neuronal differentiation gene, Syn1, suggesting a potential effect of these HDACIs on REST function. Interestingly, VPA and TSA substantially increased histone acetylation at the REST promoter and activated its transcription, whereas SAHA unexpectedly promoted its proteasomal degradation. A REST-dependent decrease in cell growth was also observed following SAHA treatment. Thus, our studies suggest that HDACIs may have therapeutic potential for patients with REST-positive tumors. This warrants further investigation.

Citing Articles

REST Is Restless in Neuronal and Non-Neuronal Virus Infections: An In Silico Analysis-Based Perspective.

Pillai V, Ravindran S, Krishna G, Abhinand C, Nelson-Sathi S, Veettil M Viruses. 2025; 17(2).

PMID: 40006989 PMC: 11860772. DOI: 10.3390/v17020234.


Exploring the promise of regulator of G Protein Signaling 20: insights into potential mechanisms and prospects across solid cancers and hematological malignancies.

Wang Y, Qin J, Sharma A, Dakal T, Wang J, Pan T Cancer Cell Int. 2024; 24(1):305.

PMID: 39227952 PMC: 11373255. DOI: 10.1186/s12935-024-03487-y.


Comprehensive analysis of the REST transcription factor regulatory networks in IDH mutant and IDH wild-type glioma cell lines and tumors.

Perycz M, Dabrowski M, Jardanowska-Kotuniak M, Roura A, Gielniewski B, Stepniak K Acta Neuropathol Commun. 2024; 12(1):72.

PMID: 38711090 PMC: 11071216. DOI: 10.1186/s40478-024-01779-y.


Protein Expression of NEK2, JMJD4, and REST in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical, Pathological, and Prognostic Findings.

Elsayed W, Harb O, Alabiad M, Faraj Saad R, Anbaig A, Alorini M Iran J Pathol. 2023; 18(2):180-192.

PMID: 37600577 PMC: 10439757. DOI: 10.30699/IJP.2023.1974154.3022.


REST in the Road Map of Brain Development.

Lam X, Maniam S, Cheah P, Ling K Cell Mol Neurobiol. 2023; 43(7):3417-3433.

PMID: 37517069 PMC: 11410019. DOI: 10.1007/s10571-023-01394-w.


References
1.
Su X, Gopalakrishnan V, Stearns D, Aldape K, Lang F, Fuller G . Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol. 2006; 26(5):1666-78. PMC: 1430235. DOI: 10.1128/MCB.26.5.1666-1678.2006. View

2.
Rikiishi H . Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol. 2011; 2011:830260. PMC: 3100649. DOI: 10.1155/2011/830260. View

3.
Carlotti Jr C, Smith C, Rutka J . The molecular genetics of medulloblastoma: an assessment of new therapeutic targets. Neurosurg Rev. 2008; 31(4):359-68. DOI: 10.1007/s10143-008-0146-4. View

4.
Suliman B, Xu D, Williams B . HDACi: molecular mechanisms and therapeutic implications in the innate immune system. Immunol Cell Biol. 2011; 90(1):23-32. DOI: 10.1038/icb.2011.92. View

5.
Schoenherr C, Anderson D . The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science. 1995; 267(5202):1360-3. DOI: 10.1126/science.7871435. View